Keith Katkin, President and CEO at AVANIR PHARMACEUTICALS, INC. (AVNR), sold 277,680 shares at $16.95 ($4.7M) on 2014-12-15, disclosed to the SEC on 2014-12-18.
Scheduled sale ($4.7M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.95 | 20,000 | $339K | 7.2% |
| 2 | $16.95 | 195,160 | $3.3M | 70.3% |
| 3 | $16.93 | 62,520 | $1.1M | 22.5% |
| Total | $16.95 avg | 277,680 | $4.7M | 100% |
| Filing → |
| SNDX | BUY | 2025-05-19 | $91K | — | Filing → |
| SNDX | SELL | 2022-10-07 | $1.5M | — | Filing → |
| SNDX | SELL | 2022-10-04 | $176K | — | Filing → |